

FOI 1976

6.11.2023

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) – 2
- Abemaciclib + Fulvestrant – 1
- Alpelisib + Fulvestrant – 0
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent – 1
- Atezolizumab + Nab-paclitaxel/Paclitaxel – 1
- Capecitabine as a single agent -12
- Eribulin as a single agent or in combination – 1
- Everolimus + Exemestane – 0
- Fulvestrant as a single agent – unable to confirm
- Lapatinib – 0
- Neratinib – 0
- Parp Inhibitors (Olaparib/Talazoparib) – 1
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) – 24
- Palbociclib + Fulvestrant – 3
- Pembrolizumab – 1
- Platinum (e.g. carboplatin or cisplatin) as a single agent – 0
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) – 7
- Ribociclib + Fulvestrant – 4
- Sacituzumab Govitecan – 3
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 15
  - Taxane and/or Anthracycline in combination – Docetaxel and Phesgo – 6
  - Paclitaxel and phesgo – 3
  - Paclitaxel and Herceptin – 1
  - Paclitaxel, carbo and pembro – 1
  - Paclitaxel and carbo – 2
- Trastuzumab as a single agent or in combination – 23
- Trastuzumab emtansine – 6
- Transtuzumab deruxtecan – 2
- Any other active systemic anti-cancer therapy – see below:-
  - ❖ Abemaciclib and tamoxifen – 5

- ❖ **Capecitabine, tucatinib and Herceptin – 2**
- ❖ **Oral vinorelbine – 1**
- ❖ **Phesgo – single agent or in combination – 19**
- ❖ **EC – 19 – NB some of these pts are on EC alone or switch at cycle 4 to docetaxel or paclitaxel and may be included in figures above.**

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)